Plain-English translation of NCT07448935 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our AL Amyloidosis research guide →This research study is looking at blood and bone marrow samples from people diagnosed with AL amyloidosis, POEMS syndrome, or multiple myeloma. Researchers want to understand how a specific protein called IGLV1-44 contributes to these serious blood diseases. By studying these samples in detail, they hope to find better ways to diagnose these conditions earlier and eventually develop new treatments.
Currently, doctors struggle to catch these rare blood diseases early and don't have enough treatment options. By understanding exactly how this protein causes damage—especially to the heart—researchers hope to create new medicines that could stop the disease from progressing.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will have blood drawn and possibly a bone marrow sample taken—procedures you may already be having as part of your regular medical care. The researchers will use these samples to study your disease at a detailed level. There are no new medications or treatments involved in this research; it is purely a study of your existing samples and medical information to help future patients.
AI-generated summary from trial data · Jul 9, 2026 · Not medical advice
Italy
Sponsor
Fondazione IRCCS Policlinico San Matteo di Pavia
Enrollment target
~100 participants
Started
November 2025
Primary completion
June 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 99 Years
Last updated on clinicaltrials.gov in May 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Mario Nuvolone, MD
Fondazione IRCCS Policlinico San Matteo di Pavia
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.